WO1998038296A1 - Method for simultaneous ligation of multiple dna fragments - Google Patents
Method for simultaneous ligation of multiple dna fragments Download PDFInfo
- Publication number
- WO1998038296A1 WO1998038296A1 PCT/IL1998/000094 IL9800094W WO9838296A1 WO 1998038296 A1 WO1998038296 A1 WO 1998038296A1 IL 9800094 W IL9800094 W IL 9800094W WO 9838296 A1 WO9838296 A1 WO 9838296A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragments
- dna
- fragment
- residue
- primers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6862—Ligase chain reaction [LCR]
Definitions
- the present invention concerns an improved method for joining a number of DNA fragments into a single, complex DNA construct in a desired predetermined directional manner in which method the actual joining of the DNA fragments is essentially a single step. More specifically, the present invention concerns an improved method for combining DNA fragments having regulatory function, such as, for example, promoters and the like, and DNA fragments encoding various proteins, such as, for example, enzymes (such as polyketide synthases), cytokines, hormones and the like, into a single construct for the purposes of cloning and expression of such a construct in a simple and rapid procedure, by way of which the various DNA fragments are connected in a predetermined direction and after joining of the fragments, there is no unwanted linker DNA between the joined fragments. Accordingly, the method of the present invention provides also for a seamless joining of DNA fragments.
- regulatory function such as, for example, promoters and the like
- DNA fragments encoding various proteins such as, for example, enzymes (such as polyketide synthases
- each of the DNA fragments is initially cleaved from larger DNA entities (DNA from plas ids, cDNA, genomic DNA) with enzymes called restriction enzymes.
- restriction enzymes enzymes called restriction enzymes.
- the desired fragments are then covalently connected together by use of an enzyme called ligase.
- a given restriction enzyme is able to cleave DNA at a specific short sequence known as a restriction site.
- restriction sites situated at random up and downstream of a desired gene (or any other sequence of choice on a given DNA entity), can be identified and then cleaved by the respective enzymes.
- the DNA sequences which constitute restriction sites are mostly palindromic, between four to eight base pair long. Most enzymes cleave the DNA within the restriction site, leaving either "blunt” or “staggered” ends, depending on the specific enzyme. DNA with a "staggered” end has a short stretch (also known as "overhang") of single -stranded DNA between two to four bases long.
- the enzyme ligase can connect, or ligate, two blunt ends of two DNA fragments (each fragment is a separate molecule) and form one longer fragment (longer molecule). Such a ligation is extremely inefficient, ligase can also ligate two molecules with staggered ends if the overhangs of these two molecules are complementary to each other. In fact, matching overhangs greatly improve ligation between molecules: the single-stranded DNA on one molecule has an affinity to the complementary single-stranded DNA on the other molecule.
- the staggered ends also known as "sticky ends", or overhangs, form non-covalent connection with one another via hydrogen bonds. Since the overhangs produced by restriction enzymes are short, these connections are weak and unstable.
- Sticky-end overhangs produced by the majority of the restriction enzymes consist of an overhang of two or four nucleotides. In theory, only fragments containing matching complementary overhangs can be connected to one another by ligase. In practice, illegitimate connections are a common occurrence. Due to the low affinity between such short single strand overhangs and consequently, due to the unstable nature of the connection between them, legitimate ligation is an inefficient process yielding a low amount of desired product. Furthermore, the palindromic nature of the sticky ends always results in undesired by-products such as
- Connecting DNA fragments with non-matching ends can be carried out by either blunting the ends by special enzymes or by adding very short, artificial DNA molecules called "linkers". These molecules are specifically designed to have an overhang that would match one fragment on one of their sides and another overhang, on the other side, that would match the other fragment. The addition of lir ers further reduces the amount of the desired product.
- each step consists of several stages: first, desired DNA fragments are cut by restriction enzymes from larger molecules. Next, two DNA fragments are ligated to each other. Since the amount of the desired fragment is low, it has to be amplified, usually by transacting cells of choice, such as, for example, bacterial cells. In order to do so, the product has to be circular DNA and has to contain certain components that will allow its amplification in bacteria. The third stage is therefore transformation of the DNA product into bacterial cells. Because of the high background of undesired product, a fourth, verification, stage has to be carried out.
- One prior art method uses single strand extensions created by adding nucleotides at the 3' end of a DNA strand in a template-independent fashion (Roychoudhury, R. Gene Amplif Anal. 2:41-83, 1981).
- the enzyme used in this method terminal transferase, will incorporate nucleotides .t the 3' hydroxyl terminus of a double-stranded DNA fragment, thus creating a single-stranded tail. Since the enzyme uses the nucleotides randomly, the only way to ensure that the single-stranded tail will be complementary to a corresponding overhang creat d on a second DNA molecule, is to provide for each extension only one of the four nucleotides.
- the overhangs created with this method must therefore be homopolymeric, so that only four types of overhangs can be used, corresponding to the residues dA, dC, dG or dT. Since the overhangs created on both termini of a DNA fragment must be identical, cloning with this method is directionless and can only involve two fragments t at are connected to each other at both ends, forming a circular molecule. Furthermore, the length of the overhangs cannot be specifically controlled. Finally, the method necessarily introduces an unwanted stretch of nucleotides into the final construct, the length of which cannot be determined exactly, making the method unsuitable for the purpose of cloning into vectors where the reading frame must be preserved.
- One of the aims of the present invention is to provide a method by which two or more fragments may be joined together in a specific predetermined directional manner, very efficiently, in which the joining step is essentially a single step and in which the junction sites between the various fragments are seamless, namely, do not contain any Linker DNA segments to provide a fully in-phase joining of one fragment to the next.
- an improved method for combining two or more DNA fragments together into a multi-DNA fragment assembly which overcomes the above-mentioned drawbacks of the prior art.
- the DNA fragments are joined in an essentially single-step joining reaction in a desired, predetermined order and in a seamless fashion.
- the present invention provides a method for the simultaneous multi-DNA fragment assembly of two or more double-stranded DNA fragments produced by a primer extension reaction, particularly the polymerase chain reaction (PCR), comprising the steps of:
- the invention also provides the above method wherein the DNA mixing step is carried out before the UDG enzyme addition step.
- the invention further provides the above method wherein the UDG enzyme addition step is carried out before the DNA mixing step.
- step (e) includes the removal of the nicked oligonucleotides from the reaction.
- One embodiment of the above method of the invention is a method wherein the said 3' complementary overhangs on said DNA fragments are generated by the addition to said fragments, the enzyme UDG to apurinate said dU residue and a second enzyme selected from endonuciease III (Endo III) or endonuclease IV (Endo IV) to generate si ⁇ gle-stranded nicks of said apurinated dU residue to provide said 3' overhangs.
- Another embodiment of the above method of the present invention is a method wherein said 3' complementary overhangs of said DNA fragments are generated by the addition to said fragments, the enzyme UDG to apurinate said dU residue and the compound N,N-dimethyl ethylenediamine to generate single-stranded nicks at said a-purinated dU residue to provide said 3' overhangs (for the role of this, and other chemical reagents in forming nicks, see McHugh and Knowland. (1995) Nucleic Acid Res., 23, 1664-1670).
- the DNA fragments to be joined are selected from two or more DNA fragments having regulatory function such as, for example, promoters, enhancers, terminators, ribosome binding sites and the like; and DNA fragments encoding proteins such as, for example, enzymes (such as citrate synthases, polyketide synthases, and succinyl-
- CoA-synthetase CoA-synthetase
- cytokines hormones and the like.
- one or more of the DNA fragments to be joined is a mutant fragment having been subjected to site directed mutagenesis during its preparation.
- a promoter carried by one DNA fragment to another DNA fragment encoding the protein of choice it is possible to produce one or more site directed mutations in the promoter sequence and this by introducing into the primers made to synthesize this promoter sequence one or more specific site-directed mutations to provide a mulated promoter sequence, or similarly, by introducing mutations into the primers made to synthesize the protein sequence, it is possible to generate a site-directed mutated protein sequence.
- J tne above method wherein at least some of said primers for the primer extension production of said DNA fragments are biotinylated at their 5' ends, and wherein when said enzyme UDG and said second enzyme or compound are added to said mixture of fragments, there is also added streptavidin, either free or bound to beads, whereby single-stranded ohgonucleotides containing at their 5' end a biotin moiety generated following the formation of said single-strand nicks at said apurinated dU residues are bound via a biotin-streptavidin connection and are effectively removed from the joining reaction.
- the present invention also provides a primer for use in any of the above- mentioned methods or embodiments thereof of the present invention, comprising at least one dU residue in place of at least one dT residue, the first of said at least one dU residue(s) being positioned at least 15 nucleotides from the 5' end of the primer.
- a primer wherein the primer is biotinylated at its 5' end.
- the present invention also provides an assembled DNA construct whenever prepared by any one of the methods or embodiments thereof as set forth hereinabove, and wherein said construct has been assembled from the joining together of a plurality of D ⁇ T A fragments according to the invention.
- the invention provides a DNA fragment comprising an overhang of at least 15 nucleotides or an end portion suitable to be converted into such an overhang.
- the invention also provides said DNA fragment, for use in the above method according to the invention.
- Illustrative, but non-limitative, examples of the above assembled DNA construct of the invention include constructs which have been assembled by the together of three DNA fragments; constructs which have been assembled by the joining together of four DNA fragments; constructs which have been assembled by the joining together of five DNA fragments, and constructs which have been assembled by the joining together of eight and more DNA fragments.
- other examples of the assembled DNA constructs of the invention include constructs as indicated above, which are in the form of a hnear DNA molecule or which are in the form of a closed circular DNA molecule.
- FIG. 1 (A-E) is a schematic flow-diagram depicting one embodiment of the preparation of the fragments, their treatment and their joining, in accordance with the method of the invention, as detailed in the Examples.
- - — depicts a single strand of the DNA fragment
- / ⁇ depicts the a-purinated site.
- Fig. 2 is a schematic illustration of a plasmid prepared in accordance with the method of the present invention, as detailed in Example 1 and 2, wherein the open bars depict the Tet fragment which may be synthesized as a single fragment from primers SEQ. ID NO. 1 (also designated 31162) and SEQ. ID NO. 5 (also designated 30402), or in the form of two subfragments, TetA and TetB from primers SEQ. ID NO. 1 and SEQ. ID NO. 4 (also designated 27341), and SEQ. ID NO. 3 (also designated 25595) and SEQ. ID NO. 5, respectively; the dark bar depicts the Amp + ColEl-ORI fragment, which is synthesized as a single fragrr 2nt from primers SEQ.
- Fig. 3 is a schematic illustration of a plasmid constructed out of eight fragments in accordance with the method of the present invention, as detailed in example 3.
- the present invention concerns an improved method for combining two or more DNA fragments together into a single DNA construct, by which method the fragments are joined in an essentially single-step joining reaction, in a desired, predetermined order and in a seamless fashion, namely, no linker DNA is inserted between the joined fragments.
- each primer is synthesized by standard, automated single-stranded (oligonucleotide) DNA synthesis and has two parts. A 3' part being complementary to the fragment to be produced, and a 5' part complementary to the terminal portion of the strand of another fragment to be specifically joined to this first fragment.
- the primers in accordance with the present invention, essentially correspond to the desired predeteimined junction region at those ends of the two fragments to be joined. In this way, for each fragment generated, a uniquu pair of primers is used.
- dU and the associated UDG and N,N-dimethyl ethylenediamine for the generation of the specific overhangs, is. the preferred choice, as all of these reagents are readily available at relatively low costs.
- any other suitable exo-sample nucleotides, and corresponding reagents to remove them and generate single-stranded overhangs as are known in the art may also be used in accordance with the present invention. See, for example, the above-referenced patents assigned to Life Technologies, Inc., in which there is described dU, UDG and various other exo-sample nucleotides and reagents for their removal.
- UDG to cause apurination of the dU residues in the PCR - generated DNA fragments
- a second enzyme which may be either endonuclease III (Endo III) or endonuclease IV (Endo IV), instead of N,N-dimethyl ethylenediamine, to nick the DNA fragments at the apurinated dU residue and thereby to generate the derxed 3' overhangs on the DNA fragments.
- overhangs of at least 15 nucleotides long are generated to e sure stable and efficient joining between the various fragments.
- overhangs of only 12 nucleotides disclosed in a copending patent application of the same applicant filed on the same day as this application (Attorney Docket 4191/96, Israeli Patent application No. 120339), the specification of which is incorporated herein by reference, it was found that when using fragments with overhangs of 12 bases, only low efficiency joining between two fragments could be achieved, and no joining between three or more fragments into a single construct could be achieved.
- such overhangs must be at least 15 nucleotides long to ensure the joining of two or more fragments together in an erficient manner.
- regions of either high mutation rates or very low mutation rates by amplifying fragments using mutagenic PCR protocols or high-fidelity enzymes, respectively.
- these fragments may encode any DNA molecule of choice.
- the fragments may encode various regulatory sequences such as, for example, promoters, enhancers, terminators or the like.
- the fragments may also encode various proteins having various biological activity of pharmaceutical or veterinary importance, for example, various metabolic enzymes (such as polyketide synthase), hormones, cytokines, and the like.
- various metabolic enzymes such as polyketide synthase
- hormones such as polyketide synthase
- cytokines cytokines
- chimeric structural and regulatory proteins for example, chimeric cytokine molecules, receptors, enzymes and the like, of improved or other desired biological activity, by combining fragments encoding different domains of such molecules from different sources.
- a multi-fragment assembly may be devised in which a new desired promoter is directly connected to a new desired DNA molecule encoding a biologically active protein in a single new construct for the purposes of enhanced expression of this new desired protein, then the construct is used to transfect/transform suitable cells of any organism of choice, for example, prokaryotic or eukaryotic cells such as bacterial or yeast cells, respectively, or mammalian, insect or any other eukaryotic cells.
- such a multifragment assembly can also be in the form of a modified bacterial or animal virus carrying one or more genes of choice for the purposes of infecting prokaryotic or eukaryotic cells of choice, and thereby introducing into these cells the gene(s) of choice.
- the PCR procedure is essentially the well known, now standard, procedure, which may be augmented by using recently described new high-fidelity DNA Polymerase enzymes, as well as newly developed, improved automated machinery for this purpose.
- any PCR procedure and reagents for use therewith may be utilized in accordance with the present invention to generate the very specific fragments which are to be combined together.
- a DNA construct of choice namely, a "custom-made" DNA construct in which any desired DNA fragment encoding any desired structural or regulatory function, can be joined in a seamless fashion to other such DNA fragments.
- any DNA construct of choice be it a hnear DNA molecule for insertion into cells directly by known techniques, or a circular DNA molecule to be used as a vector for transfecting/transforming cells of choice, or a hnear construct for insertion into another vector of choice, and any other such purpose readily apparent to any of skill in the art.
- the fragments which are to be attached to each other in a directional fashion are preferably prepared by utilizing the well-established Polymerase Chain Reaction (PCR) procedure, this being a standard procedure of the art. This provides for suitable amounts of the fragments.
- PCR Polymerase Chain Reaction
- the desired fragments of the original DNA are greatly amplified and by virtue of the use of pre-selected specific primers in the PCR procedure, the 5' and 3' ends (termini) of the PCR-prepared fragments will have the desired pre-selected sequences which will ultimately provide for the directional attachment of the fragments to yield the DNA molecule of choice, in which all of the fragments have been attached to each other in the pre-selected order.
- tlr.s necessity is also convenient for the purpose ⁇ of the present invention, namely, into these primers, one or more dU residues may be incorporated in place of one or more dT residues, these one or more dU residues being the sites at which further specific treatment will provide for each of the various fragments having the desired single-stranded DNA overhangs (cohesive ends) that will be complementary only to the overhangs on the other fragments to which each fragment is to be connected, thereby ensuring the directionahty of the connection.
- dU insertions it is preferred to use more than one such dU insertion into each primer in those sites of the primer that it is desired to treat further following the PCR procedure.
- the number of dU insertions is entirely dependent upon the chosen (pre ⁇ etermined) primer sequence, not all primer sequences of choice will necessarily have many dT residues for replacement by dU residues. Further, it is also desirable to have such dU replacements that are spread out along the length of the primer, but here too, the number and spread of dU replacements is dependent upon the primer sequences of choice. In any event, at least one dU insertion in place of one dT residue is essential in each primer sequence to ensure the successful operation of the method of the invention.
- all of the fragments are mixed together and subjected to the preferred treatment with UDG and N,N-dimethyl ethylenediamine, which results in the apurination of the dU residues, followed by cleavage (nick) at the 3' side of each apurinated residue to create a single strand nick.
- the temperature is raised to 75°C, resulting in the denaturation and disconnection of the double-stranded structures in between dU residues and up to the dU residue most distal from the 5' end of the primer (the most 3' dU residue), or when only one dU residue was inserted, then the denaturation and disconnection is up to the position of this dU residue, thereby yielding fragments having long specific 3' overhangs.
- These 21 overhangs are specific both as regards their sequence, and as regards their length, the length being determined by the original placement of the most distal (most 3') dU residue in the primer. In the present invention, overhangs of about 15 nucleotides and longer are used.
- the above predetermined annealing can be done by a slow cooling, (starting from 75°C and down to about 20-30°C), which facilitates specific and directional annealing of the different fragments to each other, by virtue of specific connections between the complementary 3' overhangs of the neighboring fragments.
- the annealing of the fragment can be done at 37°C or at any temperature desired when more than one dU residue is inserted into the primer and the inserted dU residues are spaced along the primer, their subsequent removal results in the generation of very short released oligonucleotides which compete less successfully for anneahng to the aforesaid strand (to which they were originally annealed) with the complementary overhangs of the fragments to be joined.
- the various released ohgonucleotides are less efficient in reannealing, the shorter the oligonucleotide, the less the anneahng efficiency.
- the ohgonucleotides that are generated 3' to the apurinated dU residue or residues are removed from the mixture. Two examples of how to do it are included herein, one using biotin (Example 2), the other using a different procedure (Example 3).
- hgase e.g., T ligase; of course any ligase, other than T4 hgase, may be used
- T ligase any ligase, other than T4 hgase, may be used
- This Hgase step is optional in view of the fact that by the preferred use of long overhangs at the termini of the fragments, the connection between the matching complementary overhangs, i.e., the hydrogen hor ding therebetween, is of such a nature that even without the final covalent connection with a ligase, the hydrogen bonding is strong enough to hold all of the fragments together.
- fragments combined in this fashion remain intact in a hnear form even when subjected to gel electrophoresis, or when fragments are so connected to form a circularized DNA molecule, such a circularized molecule is structurally stable enough to be used to transfect cells to provide transformed cells containing this circularized molecule, which in these cells become ligated by the endogenous cellular ligases.
- the specific primers used in the PCR step are designed in such a way that the ends that are to be connected to each other are nomologous (i.e., nave perfectly co plementary 3' overhangs, once these overhangs have been generated as noted above and below).
- the right terminus of fragment 1 should be homologous to the left terminus of fragment 2
- the right terminus of fragment 2 should be homologous to the left terminus of fragment 3
- the right terminus of fragment 3 should be homologous to the left terminus of fragment 4
- the right terminus of fragment 4 snould be homologous to the left terminus of fragment 5.
- the left terminus of fragment 1 and the right terminus of fragment 5, i.e., the extreme ends of the molecule, should not have any homology to each other or to any of the other left or right termini of all of the various fragments, in this way ensuring that the so-produced molecule will be hnear and will not be capable of circularization or undergoing any other inter-fragment interactions which would disturb the 1-2-3-4-5 desired configuration to be formed.
- the right terminus of fragment 5 should be homologous to the left terminus of fragment 1, thereby ensuring that circularization occurs only by connection between fragment 5 and fragment 1.
- the method of the present invention is essentially a single-step procedure in which all of the reaction components are present in a single reaction vessel in which all of the various reactions and treatments are carried out, thereby greatly simplifying the overall process and providing an end-product that is essentially only the desired product which can be readily obtained and fu: ;her utilized.
- the initial PCR amplification of the fragments vhich it is desired to combine should preferably be carried out in separate reaction vessels for each specific fragment to ensure the fidelity of the PCR products.
- FIG. 1 A schematic representation of the above-mentioned general procedure is set forth in Fig. 1.
- parts A-D there is illustrated how a PCR fragment having only a single dU residue (for simplicity of illustration) may be treated with UDG and N,N-dimethyl ethylenediamine to yield a PCR fragment with 3' overhangs at its two termini.
- dU residue in the end-product of the PCR procedure, i.e., the desired PCR-produced fragment which has incorporated at its terminal ends the sequence defined b" the two primers used in its preparation, and in which the dU residue is inserted distal from the terminal ends of the fragment so that once it is removed by the treatment with UDG and N,N-dimethyl ethylenediamine, schematically shown in parts C and D of Fig. 1, large single-stranded terminal overhangs will be formed, these preferably being at least 15 nucleotides in length, and more preferably about 20 or more nucleotides in length.
- DNA which was used as the template in all of the following examples was either the plasmid pBR322 or the plasmid pACYC184, both commercially available and for both the full sequence and restriction maps are available. This will be described in more detail in Example 1 below.
- **dNTP is a mixture of dATP, dTTP, dCTP and dGTP, in equimolar amounts, all obtained from commercial supphers and used in accordance with the manufacturer's instructions (Boehringer-Mannheim, Germany). It should be noted, as mentioi d above, that during the PCR amplification of the fragments, only these normal nucleotides are employed and that dUTP is not inserted at all, this having been already inserted into the above-noted primer 1 and primer 2 prior to commencement of the PCR procedure. ***The Taq DNA polymerase was also obtained from a commercial suppher and used in accordance with the manufacturer's instructions (Boehringer-Mannheim, Germany).
- 10X Buffer is the usual buffer employed in the PCR procedure and is also purchased from a commercial suppher and used in accordance with the manufacturer's instructions (Boehringer-Mannheim, Germany).
- the plasmid to be constructed was designed to have three or more different regions, each to be prepared separately by PCR amplification and then joined in a specific directional fashion to provide a circularized plasmid as the end-prod u ct.
- the sites within the primer sequences which would provide for the interconnection between the various PCR fragments were determined irrespective of any restriction enzyme sites or any other DNA sequence features at these connection sites in order to demonstrate that, in accordance with the method of the present invention, any DNA sequence at any particular site within a DNA molecule can be utilized as a connection site by preparing the necessary specific primers to provide for this connection site.
- Fig. 2 there is shown schematically the plasmid that was de ⁇ igned and produced by the method of the present invention.
- This plasmid carries three independent antibiotic resistance genes, for resistance to ampicillin
- the plasmid also carries the ColEl origin of replication (ColEl-ORI), which in this specific instance is situated next to the Amp gene, thxis these two entities constituting a single region of the plasmid.
- ColEl-ORI ColEl origin of replication
- the Tet and Cm genes constitute additional separate regions. Such a plasmid is capable of being replicated in a host cell and will endow the host celi, successfully transformed therewith, with resistance to all three types of antibiotic.
- Tet A Two fragments together constituting the Tet region being designated "Tet A” fragment of around 850 bp containing the upstream end of the Tet gene; and "Tet B” fragment of 600 bp containing the downstream end of the Tet gene; and
- Cm A Two fragments together constituting the Cm region, designated "Cm A” fragment of around 430 bp containing the upstream end of the Cm gene; and "Cm B” fragment of around 270 bp containing the downstream end of the Cm gene.
- the pBR322 sequence and plasmid (as a template) was utilized; and for the Cm region, the pACYCl84 sequence and plasmid (as a template) was used.
- the primers which will provide the overlap between the Cm and Tet genes and allow their connection to each other were designed as follows:
- primer SEQ. ID NO. 1 will enable synthesis of the Tet gene from the upstream side, inclusive of the Tet A fragment, this synthesis being in the clockwise direction with respect to the completed plasmid shown in Fig.2.
- primer SEQ. ID NO.1 has also an extension at its 5' end, as noted above, that is complementary to the Cm upstream region, to facilitate joining of the Tet and Cm genes.
- the above primer SEQ. ID NO. 2 will enable synthesis of the
- NO. 2 also has an extension at its 5' end, as noted above, that is complementary to the Tet upstream region, to facilitate joining of the
- the dU is- twenty nucleotides from the 5' end, and following UDG, N,N-dimethyl ethylenediamine treatment and heating, this entire twenty nucleotide single-stranded 5' fragment will be removed from both PCR fragments, leaving single-stranded 3' overhangs on the complementary fragments.
- a long overlap of 20 nucleotide bases generated on each of the PCR fragments to be joined by virtue of the specific placement of the dU residue in the primers to prepare the PCR fragments provides for a highly specific directional joining of these fragments, which is also a stable joint due to the length of those overlaps or overhangs.
- dT residues which may have been chosen to be replaced by a dU residue during the preparation of the specific primers. Some of the dT residues are nearer the 5' end of the primer sequence and hence would have been less favorable as they would have led to the generation of a 3' overhang having less than 20 nucleotide bases. Some of the dT residues are more distal from the 5' end of the primer sequence and hence might be even more favorable ⁇ han he one exemplified above as they will lead to generation of an even longer 3' overhang.
- the Tet gene may be generated from two separate fragments, one to be joined as above to the upstream end of the Cm gene, and one as noted below to be joined to the first Tet fragment, in a specific directional manner on one side and to the downstream end fragment on the other side.
- the primers for these other PCR fragments were specifically designed to provide for these joints.
- the following sequence as obtained from the sequence provided with the commercially obtained pBR322 plasmid, was chosen as the desired hnkage region for the two Tet fragments to provide the desired internal hnkage.
- Primer SEQ. ID NO. 5 also designated as 30402:
- Fig. 2 For the relative positions of these primers with respect to the completed constructed plasmid and the direction of synthesis from these primers during the PCR procedures, there is shown in Fig. 2 the two primers with arrows indicating their directions.
- the next desired hnkage in the plasmid to be constructed was the hnkage between the Amp -ColEl-ORI fragment, upstream of th Amp gene and the downstream of the Cm gene.
- a study of the respective sequences revealed the following as the desired sequence for the hnkage region for the PCR fragments to be produced containing the above gene regions:
- these primers were used to generate the required PCR fragments having terminal sequences inclusive of the above primer sequences.
- the next desired hnkage in the plasmid to be constructed was the internal hnkage between the two PCR fragments each having part of the Cm gene (Cm A and Cm B fragments in Fig.2).
- Cm A and Cm B fragments in Fig.2 the sequence information of the internal part of the Cm gene is available with the purchased pACYC184 plasmid.
- the following internal Cm sequence was chosen as the desired sequence for the internal joining of the PCR fragments to be produced containing the two Cm gene portions:
- these primers were used to generate the required PCR fragments having terminal sequences inclusive of the above primer sequences.
- UDG N,N-dimethyl ethylendiamine treatment and heating of these PCR fragments, 3' single-stranded overhangs of 23 nucleotide bases are generated on each PCR fragment.
- these 3' single-stranded overhangs are completely complementary, and hence will readily combine with each other to form the desired internal Cm gene hnkage.
- the nature of the complementary interaction of the 23 bases pairs is strong enough to facilitate tight binding between th . two fragments without the necessity for a subsequent hgase reaction.
- each of the above primer sequences represents but one possibility from among many which could have been equally suitable.
- primer sequences are so chosen so as to include in their sequence portions of the sequence of both of the DNA fragments it is desired to join, thereby ensuring a "seamless" joining of the two fragments, without any undesired "linker” sequence being inserted into the junction region between the two joined DNA fragments; and (c) that the primer sequences are so chosen to provide for complete complementarity only between the subsequently generated 3' overhangs of two fragments (the specific ends of these fragments) that it is desired to combine, such that when a number of fragments are to be joined in a desired pre-selected order, only the desired junctions will be possible.
- the primer sequences may have been chosen from among many possibilities, each having part of the Cm A fragment sequence and part of the Cm B fragment sequence, i.e., each primer covering the desired junction region between the Cm A and Cm B fragments.
- the junction is an internal one within a single gene region, there is even more flexibility of choice of primer sequence, as the junction point may have been pre-selected anywhere within the Cm gene.
- dT residues in addition to the exemplified one, may also have been replaced by a dU residue to provide subsequently the desired long 3' overhangs for the purposes of joining the PCR fragments generated from these primers.
- primer sequences were chosen specifically from the Cm gene sequence, there is ensured that once the generated PCR fragments are joined via their 3' overhangs, the joined fragments will contain only the Cm gene sequence, i.e., there is a "seamless" junction.
- the Amp-ColE ⁇ -ORI region fragment was prepared by standard PCR conditions using the above-noted primers SEQ. ID NO. 8 and SEQ. ID NO. 6 (see Fig. 2 for their relative positions and directionahty with respect to the completed plasmid), as well as the purchased pBR322 plasmid as the template DNA.
- the amounts of primer DNA, template DNA and other conditions of the PCR production were as noted hereinabove.
- the upstream portion of the Tet gene (the Tet A fragment shown in Fig. 2) was prepared by standard PCR conditions using the above-noted primers SEQ. ID NO. 1 and SEQ. ID NO. 4 (see Fig. 2 for their relative positions and directionahty with respect to the completed plasmid), as well as the purchased pBR322 plasmid as the template DNA.
- the amounts of primer DNA, template DNA and other conditions of the PCR procedures were as noted hereinabove.
- Tet B fragment shown in Fig. 2 The downstream portion of the Tet gene (the Tet B fragment shown in Fig. 2) was prepared by standard PCR conditions using the above-noted primers SEQ. ID NO. 3 and SEQ. ID NO. 5 (see Fig. 2 for their relative positions and directionahty, with respect to the completed plasmid), as well as the purchased pBR322 plasmid as the template DNA.
- the amounts of primers DNA, template DNA and other conditions of the PCR procedure were as noted hereinabove.
- the upstream portion of the Cm gene (the Cm A fragment shown in Fig. 2) was prepared by standard PCR conditions using the above-noted primers SEQ. ID NO. 2 and SEQ. ID NO. 9 (see Fig. 2 for their relative positions and directionahty, with respect to the completed plasmid), as well as the purchased pACYC184 plasmid as the template DNA.
- the amounts of primer DNA, template DNA and other conditions of the PCR procedures were as noted hereinabove.
- the downstream portion of the Cm gene (the Cm B fragment shown in Fig. 2) was prepared by standard PCR conditions using the above-noted primers SEQ. IE NO. 10 and SEQ. ID NO. 7 (see Fig 2 for their relative positions and directionahty, with respect to the completed plasmid), as well as the purchased pACYC184 plasmid as the template DNA.
- the amounts of primer DNA, template DNA and other conditions of the PCR procedures were as noted hereinabove.
- PCR For PCR, the following conditions and conentrations were used: lO ⁇ l of a 0.1 mg/ml solution of primer #1 and primer #2, respectively, were mixed and 180 ⁇ l of PCR mix as given below added. Then, l ⁇ l of 40ng/ ⁇ l of DNA template was added, and the PCR carried out at the temperature regime indicated below.
- each fragment was then purified by standard agarose-gel purification techniques using the commercially available Bio-Rad "Prep -A- GeneTM” UNA purification kit ana adhering to the manufacturer's instructions.
- concentration of the purified fragment DNA was determined by standard procedures using the Pharmacia "Gene-QuantTM RNA/DNA Calculator” and adhering to the manufacture's instructions.
- the 5 PCR fragments as produced and purified according to the above-mentioned procedure were connected to each other in a one-step reaction mixture in a single reaction vessel. This was achieved by mixing the fragments together. Each DNA fragment was in an amount of 0.15 pmol. The volume of the DNA fragm e nts mixture was 9 ⁇ l. 10 ⁇ l "dU nicking mixture" was added tc the DNA fragments mixture. The dU nicking mixture containing 40mM Tris-HCI pH 8.4, 100 mM KC1, 3mM MgCl 2) 200mM N,N-dimethyl ethylenediamine. 1 ⁇ l UDG (in a concentration of 5 U/ ⁇ l purchased from GibcoBRL), was then added to the reaction, and the mixture was incubated at 37°C for 30 minutes.
- the reaction mixture was subjected to conditions to facilitate dissociation of the short nicked single-stranded DNA (ohgonucleotides) from the 5' ends of the fragments in order to expose the desired 3' overhangs.
- These conditions included adding 20 ⁇ l Mineral Oil to the reaction mixture (to prevent evaporation) and then heating the reaction mixture to 75°C, at which temperature the mixture was incubated for 30 min.
- the ohgonucleotides (short single-strands) upstream of the dU residue at each end of the fragments dissociate from the remaining major portion of the fragments, leaving exposed 3' single stranded: overhangs on each end of each fragment.
- the next stage was to facilitate the completion of the specific directional joining of the fragments by coohng the above reaction mixture to 37°C (coohng from 75°C at a rate of about 2°C per hour).
- a 1 ⁇ l sample of the above reaction mixture containing the newly constructed plasmid made from joining the 5 separate fragments was used to transform suitable bacterial cells by standard procedures.
- the mode of transformation was by the preferred standard method of electroporation of E. coli DH10B cells.
- 20 ⁇ l of electrocompetent "Elr -.troMax” cells purchased from Gibco BRL
- were mixed with the above 1 ⁇ l DNA sample and subjected to electroporation in a commercially available apparatus BioRad "K_ coli Pulser Apparatus" set at 1.8 kV and operated according to the manufacturer's instructions).
- the cells were plated on a standard LB Agar plate containing 100 mM ampicilhn (to select for transformants having ampicilhn resistance by virtue of having being transformed with a DNA carrying the Amp gene)
- Example 1 In view of the results set forth in Example 1 above, it was desired to improve the procedure of plasmid construction to obtain a higher yield of fully conc- ructed plasmids from 5 original separate fragments.
- Biotinylation of the primers is carried out at the time of their synthesis, namely, a biotinylated dA residue is prepared by standard procedures or purchased from a commercial suppher, and is used in the primer synthesis reaction as the last nucleotide, i.e., the 5' terminal nucleotide (primer synthesis using automated apparatus and procedures has the synthesis in the 3'-5' direction). All the other dA residues added during primer synthesis will be normal, non-biotinylated ones. In this way, each primer so synthesized will be biotinylated only at its 5' terminal adenosine residue.
- the PCR fragments to be produced with these primers will be 5' biotinylated (two biotinylated 5' adenosine residues per fragment produced as each fragment is generated with two primers - see above procedure for the fragment prepaiation).
- biotinylated short strands may be attached to streptavidin-coated beads.
- the PCR fragments were produced by the same procedure as in Example 1, up to and including the step of treating the fragments with UDG and N,N-dimethylethylenediamine and incubating the reaction mixture at 37°C for 30 min.
- the reaction was divided at this stage into two separate vessels (one serving as a control).
- these 5' ohgonucleotides which are biotinylated are "captured” (i.e., bind tightly,) by the streptavidin molecules and are effectively removed from the "construction mixture", preventing them from competing with the fragment-fragment connections.
- the streptavidin beads, which are magnetic were removed from the reaction vessel by the simpie standard procedure of collecting and removing them with a magnet, under suitable conditions so as not to lead to any damage of the DNA fragments in the mixture.
- the plasmid to be constructed was designed to consist of eight fragments, each to be prepared separately by PCR amplification and then joined in a specific directional fashion to provide a circularized plasmid as the end-product.
- This example is similar to example 1, the difference being the number of fragments the plasmid was constructed of.
- Fig. 3 there is shown schematically the plasmid that was designed and produced by the method of the present invention.
- This plasmid carries four independent antibiotic resistance genes, for resistance to ampicilhn (Amp r gene, or hereinafter Amp) ; tetracychne (Tet r gene, or hereinafter Tet); chloramphenicol (Cm r gene, or hereinafter Cm ) and kanamycin (Kn r gene, or hereinafter Kn).
- the plasmid also carries the ColEl origin of replication (ColEl-ORI), which in this specific instance is situated next to the Amp gene. Hence, such a plasmid is capable of being rephcated in a host cell and will endow the host cell with resistance to aU four types of antibiotic.
- the AmpB fragment includes the 5' part of the Amp fragment and the ColEl-ORI sequence.
- the AmpA fragment includes the 3' part of the Amp fragment.
- the CmA fragment includes the 5' part of the Cm fragment and the CmB fragment includes the 3' part of the Cm fragment.
- the TetB fragment includes the 5' part of the Tet fragment and the TetA fragment includes the 3' part of the Tet fragment.
- the KnA fragment includes the 5' part of the Kn fragment and the KnB frag ⁇ ? "mt includes the 3' part of the Kn fragment.
- each primer consists of two regions: a 3' region complementary to the DNA to be amplified, and a 5' region complementary to the fragment it should be connect to.
- the (-) in the middle of the sequence represents the junction between the regions of the original DNA.
- Primer SEQ. ID NO. 11 also designated as 241365: internal Amp region 5'ATTGCTGCAGGCATCGTGGTGUCA 3' Primer SEQ. ID NO. 6, also designated as 3885: Cm region Amp region
- Primer SEQ. ID NO. 8 also designated as 27342:
- Primer SEQ. ID NO. 12 also designated as 241366: internal Amp region 5ACACCACGATGCCTGCAGCAAUGG 3'
- Primer SEQ. ID NO. 10 also designated as 25596:
- Primer SEQ. ID NO. 4 also designated 27341:
- Primer SEQ. ID NO. 14 also designated as 36176:
- Primer SEQ. ID NO. 16 also designated as 25953:
- each fragment was purified by standard agarose-gel purification techniques using the commercially available Bio-Rad "Prep-A-GeneTM” DNA purification kit and adhering to the manufacturer's instructions. Following purification, the concentration of the purified fragment DNA was determined by standard procedures.
- Th eight PCR fragments were connected to each other in a one-step reaction mixture in a single reaction vessel. This was achieved by mixing the fragments together in a 25 ⁇ l reaction mixture that included: 0.15 pmol of each fragment, 2.5 ⁇ l buffer (200mM Tris-HCl pH 8.4, 500 mM KC1, 15mM MgCl 2 ), 2.5 ⁇ l of 1M N,N-dimethyl ethylenediamine and 6.25 units of UDG (GibcoBRL). The mixture was incubated at 37°C for 4 hours and then transferred to 70°C for 5 minutes to facilitate dissociation of the short nicked single-stranded DNA from the 5' ends of the fragments (as explained in example 1).
- the DNA was cleaned from them with "QLAquick PCR purification kit" (QIAGEN) adhering to the manufacturer's instructions.
- QIAGEN Quality of Chemicals
- 200 ⁇ l of hot (70°C) buffer (20mM Tris-HCl pH 8.4, 50 mM KC1, 1.5mM MgCl 2 ) was added in order to minimize the reanneahng of the short nicked single-stranded DNA. This was carried out instead of the biotin-method desribed in Example 2.
- the DNA was eluted in 30 ⁇ l of sterilized water.
- the cells were plated on LB Agar plate containing 100 mM ampicilhn (to select for transformants having ampicilhn resistance by virtue of having been transformed with a DNA carrying the Amp r gene).
- LB Agar plate containing 100 mM ampicilhn (to select for transformants having ampicilhn resistance by virtue of having been transformed with a DNA carrying the Amp r gene).
- three colonies were picked and checked for resistance to chloramphenicol, tetracychne and kanamycin by plating them on Agar plates containing the appropriate antibiotics.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53747498A JP2001514498A (en) | 1997-02-27 | 1998-02-26 | Method for simultaneous ligation of multiple DNA fragments |
EP98904362A EP1000141A1 (en) | 1997-02-27 | 1998-02-26 | Method for simultaneous ligation of multiple dna fragments |
AU62286/98A AU6228698A (en) | 1997-02-27 | 1998-02-26 | Method for simultaneous ligation of multiple dna fragments |
IL13141798A IL131417A0 (en) | 1997-02-27 | 1998-02-26 | Method for simultaneous ligation of multiple dna fragments |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12033797A IL120337A0 (en) | 1997-02-27 | 1997-02-27 | Method for joining DNA fragments |
IL120337 | 1997-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998038296A1 true WO1998038296A1 (en) | 1998-09-03 |
Family
ID=11069865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL1998/000094 WO1998038296A1 (en) | 1997-02-27 | 1998-02-26 | Method for simultaneous ligation of multiple dna fragments |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1000141A1 (en) |
JP (1) | JP2001514498A (en) |
AU (1) | AU6228698A (en) |
IL (1) | IL120337A0 (en) |
WO (1) | WO1998038296A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999010358A2 (en) * | 1997-08-22 | 1999-03-04 | Peter Hegemann | Method for producing nucleic acid polymers |
EP1038974A1 (en) * | 1999-03-26 | 2000-09-27 | Mira Diagnostica GmbH | Method, oligonucleotides suitable for the degradation of in vitro synthezised nucleic acid molecules |
EP1041159A2 (en) * | 1999-03-26 | 2000-10-04 | MIRA Diagnostika GmbH | Method, oligonucleotides suitable for the degradation of in vitro synthesized nucleic acid molecules |
US6410241B1 (en) | 1999-03-24 | 2002-06-25 | Board Of Regents, The University Of Texas System | Methods of screening open reading frames to determine whether they encode polypeptides with an ability to generate an immune response |
US6825011B1 (en) | 1998-12-17 | 2004-11-30 | Yuri Rumantichikov | Methods for insertion of nucleic acids into circular vectors |
US7033753B1 (en) | 1999-01-15 | 2006-04-25 | University Of Rochester | Compositions and methods for nonenzymatic ligation of oligonucleotides and detection of genetic polymorphisms |
US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
US8143001B2 (en) | 2003-12-29 | 2012-03-27 | Nugen Technologies, Inc. | Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids |
US9206418B2 (en) | 2011-10-19 | 2015-12-08 | Nugen Technologies, Inc. | Compositions and methods for directional nucleic acid amplification and sequencing |
US9447445B2 (en) | 2014-08-27 | 2016-09-20 | New England Biolabs, Inc. | Synthon formation |
US9650628B2 (en) | 2012-01-26 | 2017-05-16 | Nugen Technologies, Inc. | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library regeneration |
US9745614B2 (en) | 2014-02-28 | 2017-08-29 | Nugen Technologies, Inc. | Reduced representation bisulfite sequencing with diversity adaptors |
US9822408B2 (en) | 2013-03-15 | 2017-11-21 | Nugen Technologies, Inc. | Sequential sequencing |
US9957549B2 (en) | 2012-06-18 | 2018-05-01 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
US9963687B2 (en) | 2014-08-27 | 2018-05-08 | New England Biolabs, Inc. | Fusion polymerase and method for using the same |
US10102337B2 (en) | 2014-08-06 | 2018-10-16 | Nugen Technologies, Inc. | Digital measurements from targeted sequencing |
US10570448B2 (en) | 2013-11-13 | 2020-02-25 | Tecan Genomics | Compositions and methods for identification of a duplicate sequencing read |
US11028430B2 (en) | 2012-07-09 | 2021-06-08 | Nugen Technologies, Inc. | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
US11629377B2 (en) | 2017-09-29 | 2023-04-18 | Evonetix Ltd | Error detection during hybridisation of target double-stranded nucleic acid |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0385410A2 (en) * | 1989-02-28 | 1990-09-05 | Canon Kabushiki Kaisha | Partially double-stranded oligonucleotide and method for forming oligonucleotide |
EP0456304A1 (en) * | 1990-05-04 | 1991-11-13 | Johnson & Johnson Clinical Diagnostics, Inc. | Preparation and isolation of single-stranded biotinylated nucleic acids by avidin-biotin cleavage |
WO1993018175A1 (en) * | 1992-03-10 | 1993-09-16 | Life Technologies, Inc. | Udg-facilitated mutagenesis |
-
1997
- 1997-02-27 IL IL12033797A patent/IL120337A0/en unknown
-
1998
- 1998-02-26 EP EP98904362A patent/EP1000141A1/en not_active Withdrawn
- 1998-02-26 AU AU62286/98A patent/AU6228698A/en not_active Abandoned
- 1998-02-26 JP JP53747498A patent/JP2001514498A/en active Pending
- 1998-02-26 WO PCT/IL1998/000094 patent/WO1998038296A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0385410A2 (en) * | 1989-02-28 | 1990-09-05 | Canon Kabushiki Kaisha | Partially double-stranded oligonucleotide and method for forming oligonucleotide |
EP0456304A1 (en) * | 1990-05-04 | 1991-11-13 | Johnson & Johnson Clinical Diagnostics, Inc. | Preparation and isolation of single-stranded biotinylated nucleic acids by avidin-biotin cleavage |
WO1993018175A1 (en) * | 1992-03-10 | 1993-09-16 | Life Technologies, Inc. | Udg-facilitated mutagenesis |
Non-Patent Citations (5)
Title |
---|
BOOTH P.M. ET AL.: "Assembly and cloning of coding sequences for neurotrophic factors directly from genomic DNA using polymerase chain reaction and uracil DNA glycosylase", GENE., vol. 146, no. 2, 1994, AMSTERDAM NL, pages 303 - 308, XP002071998 * |
NEWTON C R ET AL: "PCR", 1994, BIOS SCIENTIFIC PUBLISHERS, OXFORD GB, XP002072707 * |
RASHTCHIAN A. ET AL.: "URACIL DNA GLYCOSYLASE-MEDIATED CLONING OF POLYMERASE CHAIN REACTION-AMPLIFIED DNA: APPLICATION TO GENOMIC AND cDNA CLONING", ANALYTICAL BIOCHEMISTRY, vol. 206, no. 1, 1 October 1992 (1992-10-01), pages 91 - 97, XP000311343 * |
SMITH C. ET AL.: "Generation of cohesive ends on PCR products by UDG-mediated excision of dU, and application for cloning into restriction digest-linearized vectors", PCR METHODS & APPLICATIONS., vol. 2, no. 4, May 1993 (1993-05-01), ING HARBOR LABORATORY PRESS US, pages 328 - 332, XP002071999 * |
WATSON D.E., BENNETT G.N.: "Cloning and assemby of PCR products using modified primers and DNA repair enzymes", BIOTECHNIQUES., vol. 23, no. 5, 1997, NATICK US, pages 858 - 860, 862, 864, XP002071997 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999010358A3 (en) * | 1997-08-22 | 1999-08-05 | Peter Hegemann | Method for producing nucleic acid polymers |
WO1999010358A2 (en) * | 1997-08-22 | 1999-03-04 | Peter Hegemann | Method for producing nucleic acid polymers |
US6825011B1 (en) | 1998-12-17 | 2004-11-30 | Yuri Rumantichikov | Methods for insertion of nucleic acids into circular vectors |
US7033753B1 (en) | 1999-01-15 | 2006-04-25 | University Of Rochester | Compositions and methods for nonenzymatic ligation of oligonucleotides and detection of genetic polymorphisms |
US7049098B2 (en) | 1999-03-24 | 2006-05-23 | Board Of Regents, The University Of Texas System | Method of vaccination comprising linear and circular expression elements |
US6900018B2 (en) | 1999-03-24 | 2005-05-31 | Board Of Regents, The University Of Texas System | Method of screening for a biological response using linear and circular expression elements |
US7018833B2 (en) | 1999-03-24 | 2006-03-28 | Board Of Regents, The University Of Texas System | Linear and circular expression elements |
US6410241B1 (en) | 1999-03-24 | 2002-06-25 | Board Of Regents, The University Of Texas System | Methods of screening open reading frames to determine whether they encode polypeptides with an ability to generate an immune response |
EP1041159A3 (en) * | 1999-03-26 | 2000-10-25 | MIRA Diagnostika GmbH | Method, oligonucleotides suitable for the degradation of in vitro synthesized nucleic acid molecules |
EP1041159A2 (en) * | 1999-03-26 | 2000-10-04 | MIRA Diagnostika GmbH | Method, oligonucleotides suitable for the degradation of in vitro synthesized nucleic acid molecules |
EP1038974A1 (en) * | 1999-03-26 | 2000-09-27 | Mira Diagnostica GmbH | Method, oligonucleotides suitable for the degradation of in vitro synthezised nucleic acid molecules |
US8143001B2 (en) | 2003-12-29 | 2012-03-27 | Nugen Technologies, Inc. | Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids |
US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
US9206418B2 (en) | 2011-10-19 | 2015-12-08 | Nugen Technologies, Inc. | Compositions and methods for directional nucleic acid amplification and sequencing |
US9650628B2 (en) | 2012-01-26 | 2017-05-16 | Nugen Technologies, Inc. | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library regeneration |
US10876108B2 (en) | 2012-01-26 | 2020-12-29 | Nugen Technologies, Inc. | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation |
US10036012B2 (en) | 2012-01-26 | 2018-07-31 | Nugen Technologies, Inc. | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation |
US9957549B2 (en) | 2012-06-18 | 2018-05-01 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
US11697843B2 (en) | 2012-07-09 | 2023-07-11 | Tecan Genomics, Inc. | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
US11028430B2 (en) | 2012-07-09 | 2021-06-08 | Nugen Technologies, Inc. | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
US10760123B2 (en) | 2013-03-15 | 2020-09-01 | Nugen Technologies, Inc. | Sequential sequencing |
US10619206B2 (en) | 2013-03-15 | 2020-04-14 | Tecan Genomics | Sequential sequencing |
US9822408B2 (en) | 2013-03-15 | 2017-11-21 | Nugen Technologies, Inc. | Sequential sequencing |
US10570448B2 (en) | 2013-11-13 | 2020-02-25 | Tecan Genomics | Compositions and methods for identification of a duplicate sequencing read |
US11098357B2 (en) | 2013-11-13 | 2021-08-24 | Tecan Genomics, Inc. | Compositions and methods for identification of a duplicate sequencing read |
US11725241B2 (en) | 2013-11-13 | 2023-08-15 | Tecan Genomics, Inc. | Compositions and methods for identification of a duplicate sequencing read |
US9745614B2 (en) | 2014-02-28 | 2017-08-29 | Nugen Technologies, Inc. | Reduced representation bisulfite sequencing with diversity adaptors |
US10102337B2 (en) | 2014-08-06 | 2018-10-16 | Nugen Technologies, Inc. | Digital measurements from targeted sequencing |
US9963687B2 (en) | 2014-08-27 | 2018-05-08 | New England Biolabs, Inc. | Fusion polymerase and method for using the same |
US9447445B2 (en) | 2014-08-27 | 2016-09-20 | New England Biolabs, Inc. | Synthon formation |
US11629377B2 (en) | 2017-09-29 | 2023-04-18 | Evonetix Ltd | Error detection during hybridisation of target double-stranded nucleic acid |
US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
Also Published As
Publication number | Publication date |
---|---|
AU6228698A (en) | 1998-09-18 |
JP2001514498A (en) | 2001-09-11 |
IL120337A0 (en) | 1997-06-10 |
EP1000141A1 (en) | 2000-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998038296A1 (en) | Method for simultaneous ligation of multiple dna fragments | |
US6372429B1 (en) | Method for assembly of multiple DNA fragments | |
WO1998038297A1 (en) | Single step assembly of multiple dna fragments | |
JP3433929B2 (en) | Method for amplifying nucleic acid sequence | |
EP0550693B1 (en) | Direct cloning of pcr amplified nucleic acids | |
EP0528882B1 (en) | A thermostable ligase mediated dna amplification system for the detection of genetic diseases | |
US5830711A (en) | Thermostable ligase mediated DNA amplification system for the detection of genetic diseases | |
EP1483409B1 (en) | Method of error reduction in nucleic acid populations | |
AU645045B2 (en) | Cloning method and kit | |
EP0466083A2 (en) | Method for site-directed mutagenesis | |
KR101557975B1 (en) | Method for Amplification Nucleic Acid Using Aelle-Specific Reaction Primers | |
CN113564197B (en) | Construction method and application of CRISPR/Cas9 mediated plant polygene editing vector | |
CN113462748A (en) | Preparation method and kit of DNA sequencing library | |
CN107083427B (en) | DNA ligase mediated DNA amplification technology | |
EP1362101B1 (en) | Orientation-directed construction of plasmids | |
US20030219878A1 (en) | Sticky rice | |
Glick et al. | Molecular Genetics: Gene Isolation, Characterization and Manipulation | |
Hollenberg et al. | Primer-directed mutagenesis of linearized plasmids | |
CN117098855A (en) | Blocking oligonucleotides for selective depletion of undesired fragments from amplified libraries | |
CN115725718A (en) | Method and kit for detecting target nucleic acid | |
WO2006050062A2 (en) | Polymerase-based protocols for the introduction of deletions and insertions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 131417 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998904362 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09382435 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 537474 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998904362 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998904362 Country of ref document: EP |